In accordance with the theme education work arrangement of the Municipal Party Committee and the requirements of Daxing's investigation and research deployment, the Pudong New Area Biomedical Industry Development Symposium was held in the Zhangjiang Science Hall on the afternoon of June 5 . Zhu Zhisong, member of the Standing Committee of the Municipal Party Committee and Secretary of the District Party Committee, presided over the meeting and emphasized that the biomedical industry is one of the three leading industries that Shanghai implements the requirements of General Secretary Xi Jinping and prioritizes development. It is also the most distinctive and most advantageous six core industries in Pudong New Area As one of the industries, Pudong will start from seven aspects, including basic research, venture capital, space creation, functional platform, integration of production and medicine, system innovation, and talent gathering, to promote the biomedical industry to achieve a new leap from a new starting point.

At the symposium, Yang Jinbo, director of the Yangtze River Delta Branch Center for Drug evaluation and Inspection of the State Drug Administration, Fang Yong, deputy dean of the Shanghai Jiao Tong University School of Medicine, Zhang Zhaohui, chief operating officer of Shanghai WuXi PharmaTech New Drug Development Co., Ltd., and Chao Shengxixiang (Shanghai Dai Yingxin, chief operating officer of ) Medical Technology Co., Ltd., and other representatives of institutions and enterprises in the biomedical industry made speeches successively. Bayer (China) Co., Ltd., MicroPort Endovascular Medical Technology (Group) Co., Ltd., and Shanghai Ailis Medical Technology Co., Ltd. made written exchanges. Everyone put forward opinions and suggestions on topics such as how to strengthen innovation strategies, strengthen forward-looking layout, optimize planning layout, deepen reform and exploration, innovate synergy mechanisms, and build industrial brands.

During the exchange, Zhu Zhisong thanked everyone for their contributions to the economic and social development of Pudong and the improvement of the regional medical level. To optimize the business environment, I hope that everyone will put more core business and industrialization projects in Pudong. Zhu Zhisong pointed out that in view of the laws and characteristics of the development of the biomedical industry, Pudong will focus on seven aspects of work——

Focus on basic research, give full play to Pudong's resource advantages, attach importance to life science research and investment, consolidate the thickness of basic research, support basic research and applied basic research, and strive to form a number of original achievements from 0 to 1 ;

Focus on venture capital, make good use of Pudong’s rich venture capital resources, promote state-owned venture capital to adopt an investment strategy of early entry and fast exit, moderate profit sharing, and tolerance of risks, and support the development of innovative biomedical companies through investment and education linkage;

Focus on space creation, pay more attention to the close connection between R&D and industrialization of biopharmaceutical enterprises, provide appropriate development space according to different stages of enterprise growth, and ensure that "good projects do not lack land, and good industries do not lack space";

Focus on functional platforms, deploy a number of high-quality public service platforms in new fields such as cell genes, synthetic biology, and artificial intelligence medical research and development, strive for a wider range of review and verification services to be implemented in Pudong, and help innovative companies to travel lightly and reduce costs Increase efficiency and speed up the process of R&D and industrialization;

Focus on the integration of production and medicine, combine the advantages of Pudong's biomedical industry highland and medical highland, integrate and release the effect of " 1+1>2 ", on the one hand, promote the rapid admission and application of innovative medical devices born in Pudong, and on the other hand, promote the construction of high-level research hospitals , support medical institutions to carry out more clinical trials and clinical research;

Focus on institutional innovation, give play to the role of a series of reform platforms and legislative advantages such as leading zones, free trade zones, and comprehensive reform pilots, promote pioneering reforms, institutional opening, and integrated innovation, and use institutional innovation to promote technological innovation and industrial innovation, and help biological A new round of development of the pharmaceutical industry;

Grasp the gathering of talents, show sincere feelings, real money, and support the " 1+1+N " talent policy system to comprehensively guarantee the needs of talents in all aspects.

Before the symposium, the district leaders went to Zhangjiang Cell Industrial Park, Zhangjiang Headquarters Park, Jinsai Pharmaceutical and other new area biopharmaceutical industry development space carriers and industry enterprises to conduct in-depth investigations to learn more about the park's functional positioning, planning and development, and project construction progress.

It is reported that after more than 30 years of development, the brand influence of Pudong's biopharmaceutical industry has continued to expand. More than 2,700 upstream and downstream, large and medium-sized enterprises have integrated development, and nearly 120,000 employees in the biopharmaceutical industry have gathered here. In 2022 , the scale of the biomedical industry in Pudong New Area will be 338.2 billion yuan, accounting for 40% of the city's total . With the concentrated launch of innovative products and the accelerated release of industrial space, it is expected to continue to maintain a growth trend.

Hou Jin, the full-time deputy director of the founding department of Shanghai Branch, and Wu Qiang, the deputy head of the district, participated in related activities.